

# **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA476)**

## **NICE GUIDANCE ISSUED SEPTEMBER 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Advice No: 2414 – September 2014**

### **Paclitaxel albumin-bound nanoparticles (Abraxane<sup>®</sup>) 5 mg/ml powder for suspension for infusion**

**Submission by Celgene Ltd**

#### **Recommendation of AWMSG**

**Paclitaxel albumin-bound nanoparticles (Abraxane<sup>®</sup>) is recommended as an option for use within NHS Wales in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.**

#### **Additional note:**

- AWMSG acknowledged that the AWMSG criteria for appraising life-extending, end-of-life medicines applied to paclitaxel albumin-bound nanoparticles (Abraxane<sup>®</sup>) for the indication under consideration.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1999), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review in three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2414:  
Paclitaxel albumin-bound nanoparticles®) 5 mg/ml powder for suspension for infusion.  
September 2014.

